Providence, RI - Together, Butler Hospital and Rhode Island Hospital are participating in The ADvance Study, a clinical trial investigating the use of deep brain stimulation (DBS) as a treatment for patients with Alzheimer's disease. The collaborative study between the two hospitals is part of a multisite clinical trial investigating the safety and efficacy of DBS in slowing the loss of memory and cognition in patients with Alzheimer's disease, a disease which currently afflicts more than 5 million people in the US and for which there is no cure.
A device currently used to treat other brain-related conditions, DBS is often described as a 'pacemaker for the brain,' as it uses an implanted device to electronically stimulate the brain. In the ADvance Study, a pacemaker-like device is implanted beneath the skin in the patient's chest to deliver electrical pulses directly to the fornix- a part of the brain that plays a central role in memory. DBS is currently FDA approved to treat Parkinson's disease, Tourette's syndrome and resistant Obsessive Compulsive Disorder.
"Alzheimer's researchers from around the world, including those at Butler and Rhode Island Hospital, are committed to developing safe and effective treatments for Alzheimer's disease," said Stephen Salloway, MD, principal investigator for the study and director of the Memory and Aging Program at Butler Hospital. "DBS has helped transform the treatment of Parkinson's disease and we hope that stimulation of memory circuits can have a similar benefit in treating Alzheimer's disease." Salloway notes that the approach in this study differs from medications and vaccines that are being investigated for Alzheimer's disease. DBS uses a device that has already been safety-checked and FDA approved for treating other conditions and has been shown to be safe in early studies with Alzheimer's patients.
This clinical trial stems from a preliminary DBS study in six patients with Alzheimer's disease in Canada. That study found that patients with mild forms of the disease showed sustained increases in glucose metabolism, an indicator of neuronal activity, over a 13-month period. Most patients with Alzheimer's disease show decreases in glucose metabolism over the same time period.
In the double-blind clinical trial being conducted at Butler and Rhode Island Hospital, all participants will have the device implanted. Half of the participants will have the device activated in the first year, and all participants will receive active stimulation in the second year of the study. Following an initial evaluation at Butler, participants will have the device implanted at Rhode Island Hospital under the direction of Garth Rees Cosgrove, MD, chief of neurosurgery at Rhode Island Hospital, Chairman of the Department of Neurosurgery at Warren Alpert Medical School of Brown University, and Director of the Norman Prince Neuroscience Institute at Rhode Island Hospital.
"The results of the preliminary trial are very encouraging," said Dr. Cosgrove. "We have seen tremendous success in using deep brain stimulation on many of our patients with other neurological illnesses such as Parkinson's disease, and it has truly been a life-changing treatment. If we can achieve a similar response with our Alzheimer's patients then we will have the opportunity to improve millions of lives."
After the device is implanted, participants will visit Butler to have the device programmed by Victoria Chang, MD, a neurologist with expertise in DBS programming. Researchers at Butler will monitor safety outcomes and changes in memory, cognition and daily functioning with brain scans performed at Rhode Island Hospital. "This study is an example of a true collaborative effort between our two hospitals and health care systems to make progress against a devastating illness," said Dr. Salloway.
Butler and RIH are currently recruiting patients with mild Alzheimer's disease for The ADvance Study. Eligible participants must have mild Alzheimer's disease, be aged 55 to 80 years old, live at home, currently taking medication for Alzheimer's and have a caregiver who can accompany them to doctor visits. For information about participating in the study, patients and/or caregivers can call 401-455-6403, email Diane Monast, RN, MSN at DMonast@Butler.org or log onto http://www.
About Butler Hospital
Butler Hospital is the only private, nonprofit psychiatric and substance abuse hospital serving adults, seniors and adolescents in Rhode Island and southeastern New England. Founded in 1844, it was the first hospital in Rhode Island and has earned a reputation as the leading provider of innovative psychiatric treatments in the region. The Major Affiliated Teaching Hospital for Psychiatry and Behavioral Health at The Warren Alpert Medical School of Brown University, Butler is recognized worldwide as a pioneer in conducting cutting-edge research.
About Rhode Island Hospital
Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $55 million in external research funding. It is also home to Hasbro Children's Hospital, the state's only facility dedicated to pediatric care. For more information on Rhode Island Hospital, visit http://www.
About Functional Neuromodulation Ltd.
Founded in Toronto, Ontario in 2010, Functional Neuromodulation is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with Alzheimer's and other memory and cognitive disorders. The Company has received funding from Genesys Capital, Foundation Medical Partners and Medtronic. The ADvance Study is also supported through a translational grant from the National Institute on Aging, part of the National Institutes of Health. Functional Neuromodulation has entered into a partnership with Medtronic, under which Medtronic is providing its state-of-the-art DBS devices for the ADvance Study and access to Medtronic's related device regulatory filings. For more information, visit http://www.
Ellen M. Slingsby
Rhode Island Hospital